- £1.18bn
- £1.38bn
- £2.97bn
- 83
- 80
- 89
- 98
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,301 | 2,063 | 2,223 | 2,945 | 2,966 |
Cost of Revenue | |||||
Gross Profit | 1,602 | 1,465 | 1,511 | 1,890 | 2,012 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2,226 | 1,986 | 2,146 | 2,877 | 2,813 |
Operating Profit | 74.1 | 77 | 76.4 | 67.8 | 153 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 51.6 | 63.8 | 67.5 | 56.3 | 126 |
Provision for Income Taxes | |||||
Net Income After Taxes | 21.7 | 41.1 | 55.6 | 45 | 89.8 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 21.4 | 42.5 | 56.5 | 46 | 89.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 21.4 | 42.5 | 56.5 | 46 | 89.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.659 | 0.985 | 0.966 | 1.04 | 1.44 |
Dividends per Share |